In the past decade, the discoveries of driver gene mutations, such as epidermal growth factor receptor (EGFR) and kirsten rat sarcoma viral oncogene homolog (KRAS), and corresponding molecule-targeted therapies have dramatically improved the prognosis of a portion of NSCLC patients 4. Here, EGFR is linked to non-small cell lung carcinoma.